Gornitzky represented Oppenheimer in MediWound Ltd.’s U.S. $11.2 million underwritten follow-on public offering of ordinary shares on Nasdaq.
MediWound is a biopharmaceutical company that develops, manufactures and commercializes novel bio-therapeutic solutions for tissue repair and regeneration.
Oppenheimer & Co. Inc. acted as sole book-running manager for the offering.
The underwriters were represented by partners Chaim Friedland, Ari Fried and Dr. Assaf Prussak, along with associates Desiree Reichman and Hadas Arzi.
